Robert P. Mauch Sells 4,970 Shares of Cencora, Inc. (NYSE:COR) Stock

Cencora, Inc. (NYSE:COR - Get Free Report) CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the transaction, the chief executive officer now directly owns 51,070 shares in the company, valued at $13,022,850. The trade was a 8.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cencora Trading Down 0.8 %

COR stock traded down $2.03 during midday trading on Tuesday, hitting $253.35. The company had a trading volume of 1,707,405 shares, compared to its average volume of 1,505,253. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $262.26. The stock has a market cap of $49.13 billion, a price-to-earnings ratio of 36.04, a PEG ratio of 1.31 and a beta of 0.49. The stock's 50 day moving average price is $242.26 and its 200 day moving average price is $237.98.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.87%. Cencora's dividend payout ratio is currently 31.29%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of COR. JFS Wealth Advisors LLC increased its stake in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares during the period. Banque Transatlantique SA bought a new stake in Cencora in the fourth quarter valued at $29,000. SBI Securities Co. Ltd. purchased a new position in Cencora during the 4th quarter valued at $30,000. Kentucky Trust Co bought a new position in Cencora in the 4th quarter worth $33,000. Finally, Householder Group Estate & Retirement Specialist LLC lifted its position in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after purchasing an additional 69 shares during the period. Hedge funds and other institutional investors own 97.52% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on COR. UBS Group upped their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Wells Fargo & Company upped their price objective on Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a report on Wednesday, January 29th. Evercore ISI raised their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Barclays boosted their target price on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Finally, Robert W. Baird increased their price target on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Cencora presently has an average rating of "Moderate Buy" and an average price target of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.